Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is poised for success in the biotech market as they continue to advance their RaniPill platform, which has shown promising results in bioequivalence studies. However, the company faces potential clinical and competitor risks in their pipeline, especially as they rely on generic or biosimilar APIs. Additionally, investors should keep an eye on management stability, as high turnover could hinder progress and negatively impact share performance.

Bears say

Rani Therapeutics Hldgs is facing several fundamental challenges that contribute to a negative outlook on their stock: their reliance on well-established biologics and potential pricing pressure, competitive landscape and potential reticence for adoption of their technology, and risks related to clinical development, regulatory approvals, partnering, and financing. While the company has recently raised capital and initiated a Phase 1 trial for their obesity drug candidate, the success and market traction of their oral delivery technology remains uncertain. Furthermore, the company's conservative valuation and probability of success assumptions may hinder potential upside.

RANI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 4 analysts, RANI has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.